Dr. Turner joined Quintiles after serving as the chairman of the Department of Clinical Research at Campbell University School of Pharmacy. Prior to that he was a principal clinical submissions scientist at GlaxoSmithKline, where he received awards for his work on the GlaxoSmithKline Clinical Trial Registry and in new product development.
Dr. Turner received his PhD in Cardiovascular Behavioral Medicine from the University of Birmingham, UK. His program of experimental clinical research led to 50 peer-reviewed publications and the receipt of two international research awards, from the Society for Psychophysiological Research and the American Psychosomatic Society. He is very interested in the integration of behavioral medicine and biopharmaceutical medicine approaches for the continued enhancement of patient health and well-being.
Since entering the biopharmaceutical industry he has published extensively in peer-reviewed and professional journals, and authored six books addressing statistical and methodological aspects of randomized concurrently-controlled clinical trials.
His primary area of expertise in the pharmaceutical industry is the cardiovascular safety of noncardiovascular drugs. He has published widely on this topic, including co-authoring a recent book entitled “Cardiovascular Safety in Drug Development and Therapeutic Use: New Methodologies and Evolving Regulatory Landscapes,” co-authors with Quintiles’ colleagues Dr Dilip Karnad and Dr Snehal Kothari. His work in this area was instrumental in the recent award of a Doctor of Science (DSc) degree from the University of Sheffield. This is the highest scientific degree that can be awarded in the British education system.
Dr Turner is a Fellow of the Society of Behavioral Medicine, the American Society of Hypertension, and the American College of Cardiology.